Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 10, 2023

SELL
$127.59 - $203.08 $655,812 - $1.04 Million
-5,140 Reduced 22.47%
17,733 $3.59 Million
Q4 2022

Feb 14, 2023

BUY
$117.37 - $139.17 $1.6 Million - $1.89 Million
13,591 Added 146.42%
22,873 $2.94 Million
Q3 2022

Nov 14, 2022

BUY
$135.27 - $180.11 $1.26 Million - $1.67 Million
9,282 New
9,282 $1.27 Million
Q2 2022

Aug 12, 2022

SELL
$108.81 - $179.33 $525,552 - $866,163
-4,830 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$119.61 - $157.85 $577,716 - $762,415
4,830 New
4,830 $696,000
Q2 2021

Aug 12, 2021

SELL
$135.08 - $161.1 $4.7 Million - $5.6 Million
-34,771 Closed
0 $0
Q1 2021

May 12, 2021

BUY
$137.51 - $190.8 $4.78 Million - $6.63 Million
34,771 New
34,771 $4.83 Million

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Ergoteles LLC Portfolio

Follow Ergoteles LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ergoteles LLC with notifications on news.